Entasis Therapeutics (ETTX) Reaches New 52-Week Low at $5.60

Share on StockTwits

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX)’s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $5.60 and last traded at $5.84, with a volume of 97138 shares. The stock had previously closed at $6.05.

ETTX has been the topic of a number of research reports. Credit Suisse Group initiated coverage on shares of Entasis Therapeutics in a report on Monday, October 22nd. They issued an “outperform” rating and a $18.00 price objective on the stock. SunTrust Banks initiated coverage on shares of Entasis Therapeutics in a report on Wednesday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. BMO Capital Markets initiated coverage on shares of Entasis Therapeutics in a report on Monday, October 22nd. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Wedbush initiated coverage on shares of Entasis Therapeutics in a report on Monday, October 22nd. They issued an “outperform” rating and a $19.00 price objective on the stock.

Entasis Therapeutics (NASDAQ:ETTX) last posted its quarterly earnings data on Wednesday, November 14th. The company reported ($20.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($19.18). Equities research analysts anticipate that Entasis Therapeutics Holdings Inc will post -4.68 EPS for the current year.

In other news, insider Group Holdings (Sbs) Advis Tpg purchased 262,539 shares of the stock in a transaction on Friday, September 28th. The shares were acquired at an average price of $15.00 per share, with a total value of $3,938,085.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Nicholas Galakatos purchased 453,395 shares of the stock in a transaction on Friday, September 28th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $6,800,925.00. The disclosure for this purchase can be found here. Insiders have acquired 1,805,769 shares of company stock worth $27,086,535 in the last ninety days.

Several hedge funds have recently added to or reduced their stakes in the company. Sofinnova Ventures Inc purchased a new position in shares of Entasis Therapeutics in the third quarter worth $12,840,000. Luminus Management LLC purchased a new position in shares of Entasis Therapeutics in the third quarter worth $2,130,000. Hound Partners LLC purchased a new position in shares of Entasis Therapeutics in the third quarter worth $1,117,000. Credit Suisse AG purchased a new position in shares of Entasis Therapeutics in the third quarter worth $757,000. Finally, Laurion Capital Management LP purchased a new position in shares of Entasis Therapeutics in the third quarter worth $544,000. 66.61% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Entasis Therapeutics (ETTX) Reaches New 52-Week Low at $5.60” was originally published by Week Herald and is the property of of Week Herald. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://weekherald.com/2018/12/19/entasis-therapeutics-ettx-reaches-new-52-week-low-at-5-60.html.

About Entasis Therapeutics (NASDAQ:ETTX)

Entasis Therapeutics Holdings Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing ETX2514SUL, a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, an oral antibiotic monotherapy that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and various antibiotics for gram-negative infections.

Featured Article: How to invest in a bear market

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply